Redhill Biopharma Ltd. (RDHL) Set to Announce Earnings on Monday
Redhill Biopharma Ltd. (NASDAQ:RDHL) is scheduled to be releasing its earnings data before the market opens on Monday, November 13th. Analysts expect Redhill Biopharma to post earnings of ($0.72) per share for the quarter.
Redhill Biopharma Ltd. (NASDAQ:RDHL) opened at $5.35 on Friday. Redhill Biopharma Ltd. has a 52-week low of $5.17 and a 52-week high of $12.23.
ILLEGAL ACTIVITY NOTICE: “Redhill Biopharma Ltd. (RDHL) Set to Announce Earnings on Monday” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/redhill-biopharma-ltd-rdhl-set-to-announce-earnings-on-monday/1694636.html.
Several research firms have weighed in on RDHL. HC Wainwright set a $33.00 price objective on shares of Redhill Biopharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Roth Capital set a $27.00 price objective on shares of Redhill Biopharma and gave the stock a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research cut shares of Redhill Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, July 29th. Seaport Global Securities began coverage on shares of Redhill Biopharma in a research report on Friday, October 6th. They set a “buy” rating and a $19.00 price objective on the stock. Finally, UBS AG began coverage on shares of Redhill Biopharma in a research report on Wednesday, September 13th. They set a “reduce” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Redhill Biopharma has an average rating of “Buy” and an average price target of $23.35.
About Redhill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.